Target intelligence / Profile preview

Hepatitis C virus NS3-4A serine protease (NS3-4A)

Target
NS3-4A
Molecular classification
Enzyme, Serine protease, Viral protease
01

Overview

The Hepatitis C virus NS3-4A serine protease is a membrane-associated, multifunctional viral enzyme composed of the N-terminal protease domain of NS3 and its essential cofactor, NS4A. The NS3-4A complex is crucial for the proteolytic processing of the HCV polyprotein at four specific junctions (NS3-NS4A, NS4A-NS4B, NS4B-NS5A, NS5A-NS5B), liberating nonstructural proteins required for viral RNA replication. The NS3 region also possesses an RNA helicase domain required for unwinding viral RNA. NS4A serves both as a membrane anchor and as a structural cofactor that activates and stabilizes the serine protease domain. These activities are essential for HCV replication and allow the virus to subvert innate host immune responses, for example by proteolytically degrading host factors such as TRIF involved in interferon signaling pathways. NS3-4A serine protease is a clinically validated drug target, and several direct-acting antiviral inhibitors targeting this enzyme have transformed HCV therapy. Resistance can arise through point mutations in the protease active site or inhibitor-binding regions.

Other names
NS3/4A proteaseHCV NS3-4A proteaseNS3-4A proteinaseHepatitis C virus nonstructural protein 3-4A protease
02

Mechanism of action

Direct inhibition of protease activity, leading to interruption of viral polyprotein processing and HCV replication; Prevention of cleavage of host immune factors (e.g., TRIF), restoring host immune responses

03

Biological functions

Proteolytic processing of viral polyproteinRNA helicase activityImpairment of host innate immune response
04

Disease associations

Infection (specifically Hepatitis C virus infection)
05

Safety considerations

Development of viral resistanceDrug-drug interactions (especially with other medications metabolized by the liver)Potential liver toxicity in patients with advanced liver disease
06

Interacting drugs

Boceprevir

6 more in the full profile.

07

Biomarkers

HCV RNA levels for efficacyResistance-associated substitutions (e.g., A156T, R155Q, D168V mutations in NS3)

Beyond the preview

Go deeper on Hepatitis C virus NS3-4A serine protease (NS3-4A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis C virus NS3-4A serine protease (NS3-4A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call